The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists has been further updated to highlight the potential risk o… This content is
This is mainly useful for treatment counselling, patient questions, and expectation-setting in metabolic care.
ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.